PolmanCHO’ConnorPWHavrdovaE. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354(9): 899–910.
2.
ColesAJCompstonDASelmajKW. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med2008; 359(17): 1786–1801.
3.
ColesAJFoxEVladicA. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology2012; 78(14): 1069–1078.
4.
TuohyOCostelloeLHill-CawthorneG. Alemtuzumab treatment of multiple sclerosis: Long-term safety and efficacy. J Neurol Neurosur Ps2015; 86(2): 208–215.
SaccardiRMancardiGLSolariA. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: Impact on disease activity and quality of life. Blood2005; 105(6): 2601–2607.
7.
BurtRKLohYCohenB. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study. Lancet Neurol2009; 8: 244–253.
8.
MancardiGSormaniMDiGM. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: The Italian multi-centre experience. Mult Scler2012; 18(6): 835–842.
9.
NashRAHuttonGJRackeMK. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): A 3-year interim report. JAMA Neurol2015; 72(2): 159–169.
10.
MancardiGLSormaniMPGualandiF. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. Neurology2015; 84(10): 981–988.
